Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

NCT00492258 is registered in ClinicalTrials.gov with Medical Research Council as lead sponsor.

NCT NCT00492258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00492258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
Lead sponsor
Medical Research Council
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2012
Enrollment
1,656 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer